Total Payments
$135,935
2024 Payments
$15,297
Companies
46
Transactions
978
Medicare Patients
15,376
Medicare Billing
$4.3M
Payment Breakdown by Category
Other$85,462 (62.9%)
Food & Beverage$25,852 (19.0%)
Consulting$20,557 (15.1%)
Travel$4,026 (3.0%)
Education$36.93 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Honoraria | $57,412 | 29 | 42.2% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $28,050 | 15 | 20.6% |
| Food and Beverage | $25,852 | 893 | 19.0% |
| Consulting Fee | $20,557 | 18 | 15.1% |
| Travel and Lodging | $4,026 | 18 | 3.0% |
| Education | $36.93 | 5 | 0.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Horizon Therapeutics plc | $34,192 | 98 | $0 (2023) |
| Ironwood Pharmaceuticals, Inc | $24,622 | 29 | $0 (2018) |
| Pacira Therapeutics, Inc. | $18,094 | 24 | $0 (2021) |
| Amgen Inc. | $14,957 | 131 | $0 (2024) |
| PFIZER INC. | $12,022 | 100 | $0 (2024) |
| Flexion Therapeutics, Inc. | $10,707 | 23 | $0 (2020) |
| Takeda Pharmaceuticals America, Inc. | $6,809 | 6 | $0 (2017) |
| GlaxoSmithKline, LLC. | $1,845 | 76 | $0 (2024) |
| UCB, Inc. | $1,688 | 58 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $1,618 | 86 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $15,297 | 155 | Amgen Inc. ($13,194) |
| 2023 | $14,978 | 143 | Horizon Therapeutics plc ($12,222) |
| 2022 | $13,712 | 159 | Horizon Therapeutics plc ($10,897) |
| 2021 | $26,194 | 121 | Pacira Therapeutics, Inc. ($18,094) |
| 2020 | $10,971 | 87 | Flexion Therapeutics, Inc. ($7,343) |
| 2019 | $8,219 | 100 | Flexion Therapeutics, Inc. ($3,210) |
| 2018 | $29,209 | 104 | Ironwood Pharmaceuticals, Inc ($24,622) |
| 2017 | $17,355 | 109 | PFIZER INC. ($7,864) |
All Payment Transactions
978 individual payment records from CMS Open Payments — Page 1 of 40
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/19/2024 | Amgen Inc. | Enbrel (Biological), Otezla | Food and Beverage | In-kind items and services | $20.16 | General |
| Category: Inflammation | ||||||
| 12/18/2024 | GENZYME CORPORATION | KEVZARA (Biological) | Food and Beverage | In-kind items and services | $22.84 | General |
| Category: Rheumatology | ||||||
| 12/17/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $24.19 | General |
| Category: Immunology | ||||||
| 12/16/2024 | Amgen Inc. | KRYSTEXXA (Biological) | Food and Beverage | In-kind items and services | $18.34 | General |
| Category: Inflammation/Rare Disease | ||||||
| 12/12/2024 | Octapharma USA, Inc. | OCTAGAM IMMUNE GLOBULIN (HUMAN) (Biological) | Food and Beverage | In-kind items and services | $20.00 | General |
| Category: IMMUNOLOGY | ||||||
| 12/12/2024 | Amgen Inc. | Enbrel (Biological), Otezla | Food and Beverage | In-kind items and services | $14.81 | General |
| Category: Inflammation | ||||||
| 12/11/2024 | PFIZER INC. | XELJANZ (Drug) | Food and Beverage | In-kind items and services | $12.48 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 12/09/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $18.77 | General |
| Category: Immunology | ||||||
| 12/05/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $24.79 | General |
| Category: Immunology | ||||||
| 11/26/2024 | GlaxoSmithKline, LLC. | BENLYSTA (Biological), NUCALA | Food and Beverage | In-kind items and services | $16.30 | General |
| Category: IMMUNOLOGY | ||||||
| 11/21/2024 | Novartis Pharmaceuticals Corporation | COSENTYX (Drug) | Food and Beverage | In-kind items and services | $43.11 | General |
| Category: Dermatology | ||||||
| 11/20/2024 | Mallinckrodt Hospital Products Inc. | ACTHAR (Biological) | Food and Beverage | In-kind items and services | $16.91 | General |
| Category: IMMUNOLOGY | ||||||
| 11/19/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $16.42 | General |
| Category: Immunology | ||||||
| 11/19/2024 | Amgen Inc. | Enbrel (Biological), Otezla | Food and Beverage | In-kind items and services | $15.97 | General |
| Category: Inflammation | ||||||
| 11/18/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $26.01 | General |
| Category: Immunology | ||||||
| 11/13/2024 | Amgen Inc. | KRYSTEXXA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,700.00 | General |
| Category: Inflammation/Rare Disease | ||||||
| 11/13/2024 | Amgen Inc. | KRYSTEXXA (Biological) | Food and Beverage | In-kind items and services | $18.16 | General |
| Category: Inflammation/Rare Disease | ||||||
| 11/11/2024 | PFIZER INC. | XELJANZ (Drug) | Food and Beverage | In-kind items and services | $14.32 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 11/07/2024 | Amgen Inc. | KRYSTEXXA (Biological) | Food and Beverage | In-kind items and services | $124.99 | General |
| Category: Inflammation/Rare Disease | ||||||
| 11/07/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $17.83 | General |
| Category: Immunology | ||||||
| 11/06/2024 | Amgen Inc. | Enbrel (Biological), Otezla | Food and Beverage | In-kind items and services | $19.65 | General |
| Category: Inflammation | ||||||
| 11/05/2024 | Organon Llc | HADLIMA (Drug) | Food and Beverage | In-kind items and services | $19.01 | General |
| Category: ADALIMUMAB-BWWD | ||||||
| 10/30/2024 | Amgen Inc. | KRYSTEXXA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,700.00 | General |
| Category: Inflammation/Rare Disease | ||||||
| 10/30/2024 | Amgen Inc. | TAVNEOS (Drug) | Food and Beverage | In-kind items and services | $17.55 | General |
| Category: Inflammation | ||||||
| 10/29/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $18.04 | General |
| Category: Immunology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 41 | 3,461 | 99,175 | $5.0M | $1.3M |
| 2022 | 44 | 3,882 | 63,993 | $3.8M | $1.0M |
| 2021 | 43 | 4,081 | 39,112 | $3.4M | $1.1M |
| 2020 | 40 | 3,952 | 27,264 | $2.6M | $931,482 |
Total Patients
15,376
Total Services
229,544
Medicare Billing
$4.3M
Procedure Codes
168
All Medicare Procedures & Services
168 procedure records from CMS Medicare Utilization — Page 1 of 7
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J0129 | Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 2023 | 42 | 11,850 | $1.6M | $396,222 | 25.0% |
| J1602 | Injection, golimumab, 1 mg, for intravenous use | Office | 2023 | 35 | 19,383 | $929,376 | $194,507 | 20.9% |
| J0717 | Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 2023 | 18 | 31,400 | $596,600 | $122,906 | 20.6% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 58 | 5,040 | $211,680 | $91,526 | 43.2% |
| J3262 | Injection, tocilizumab, 1 mg | Office | 2023 | 15 | 19,714 | $335,121 | $90,780 | 27.1% |
| Q5104 | Injection, infliximab-abda, biosimilar, (renflexis), 10 mg | Office | 2023 | 18 | 2,636 | $312,970 | $77,794 | 24.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 397 | 876 | $221,628 | $75,008 | 33.8% |
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | Office | 2023 | 21 | 2,672 | $304,608 | $69,569 | 22.8% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 129 | 420 | $167,580 | $41,070 | 24.5% |
| J7323 | Hyaluronan or derivative, euflexxa, for intra-articular injection, per dose | Office | 2023 | 25 | 134 | $41,674 | $13,478 | 32.3% |
| 96401 | Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 74 | 241 | $53,502 | $13,396 | 25.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 152 | 187 | $31,042 | $11,917 | 38.4% |
| 20611 | Aspiration and/or injection of fluid large joint using ultrasound guidance | Office | 2023 | 41 | 130 | $34,496 | $11,677 | 33.9% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 67 | 67 | $33,299 | $8,246 | 24.8% |
| 86235 | Measurement of antibody for assessment of autoimmune disorder, any method | Office | 2023 | 86 | 454 | $19,976 | $7,867 | 39.4% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2023 | 373 | 745 | $19,370 | $7,643 | 39.5% |
| 90677 | Pneumococcal conjugate vaccine, 20 valent (pcv20), for intramuscular use | Office | 2023 | 20 | 20 | $5,980 | $5,638 | 94.3% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 344 | 677 | $13,540 | $5,111 | 37.7% |
| 86147 | Cardiolipin antibody (tissue antibody) measurement | Office | 2023 | 40 | 120 | $7,560 | $2,993 | 39.6% |
| 86146 | Beta 2 glycoprotein 1 antibody (autoantibody) measurement | Office | 2023 | 39 | 117 | $7,371 | $2,918 | 39.6% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2023 | 37 | 137 | $11,645 | $2,905 | 24.9% |
| 20610 | Aspiration and/or injection of fluid from large joint | Office | 2023 | 49 | 59 | $6,962 | $2,884 | 41.4% |
| 86140 | Measurement c-reactive protein for detection of infection or inflammation | Office | 2023 | 295 | 558 | $7,812 | $2,802 | 35.9% |
| 86160 | Measurement of complement (immune system proteins), antigen, | Office | 2023 | 63 | 194 | $5,626 | $2,260 | 40.2% |
| 83516 | Analysis of substance using immunoassay technique, multiple step method | Office | 2023 | 93 | 188 | $5,264 | $2,106 | 40.0% |
About Dr. Thomas Rennie, M.D
Dr. Thomas Rennie, M.D is a Rheumatology healthcare provider based in San Antonio, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 11/02/2005. The National Provider Identifier (NPI) number assigned to this provider is 1265423982.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Thomas Rennie, M.D has received a total of $135,935 in payments from pharmaceutical and medical device companies, with $15,297 received in 2024. These payments were reported across 978 transactions from 46 companies. The most common payment nature is "Honoraria" ($57,412).
As a Medicare-enrolled provider, Rennie has provided services to 15,376 Medicare beneficiaries, totaling 229,544 services with total Medicare billing of $4.3M. Data is available for 4 years (2020–2023), covering 168 distinct procedure/service records.
Ad
Practice Information
- Specialty Rheumatology
- Location San Antonio, TX
- Active Since 11/02/2005
- Last Updated 07/29/2024
- Taxonomy Code 207RR0500X
- Entity Type Individual
- NPI Number 1265423982
Products in Payments
- KRYSTEXXA (Biological) $43,870
- Zilretta (Drug) $28,801
- DUZALLO (Drug) $24,622
- LYRICA (Drug) $10,692
- Uloric (Drug) $7,829
- BENLYSTA (Biological) $1,845
- Cimzia (Drug) $1,514
- Enbrel (Biological) $1,256
- ACTHAR (Biological) $1,198
- XELJANZ (Drug) $1,079
- COSENTYX (Biological) $882.36
- Rituxan (Biological) $689.35
- TALTZ (Drug) $646.08
- COSENTYX (Drug) $631.95
- TREMFYA (Drug) $581.75
- PURIFIED CORTROPHIN GEL (Drug) $578.05
- KEVZARA (Drug) $476.45
- EUFLEXXA (Device) $465.42
- Actemra (Biological) $394.69
- SAPHNELO (Biological) $391.90
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Rheumatology Doctors in San Antonio
Dr. Pendleton Wickersham, M.d, M.D
Rheumatology — Payments: $1.1M
Rheumatology $1.1M
Dr. Alex De Jesus, Md, MD
Rheumatology — Payments: $273,995
Rheumatology $273,995
Kevin Kempf, Md, MD
Rheumatology — Payments: $154,966
Rheumatology $154,966
Dr. Fernando Silva, M.d, M.D
Rheumatology — Payments: $53,617
Rheumatology $53,617
Everett Allen, Md, MD
Rheumatology — Payments: $28,103
Rheumatology $28,103
Dr. Emily Pineda, M.d, M.D
Rheumatology — Payments: $20,974
Rheumatology $20,974